Logo

MTLS

Materialise N.V.

MTLS

Materialise N.V. • NASDAQ
$6.03 ▲ 0.17% (+0.01)
Market Cap $356.18 M
52w High $9.69
52w Low $3.93
Dividend Yield 0%
P/E 67
Volume 51.56K
Outstanding Shares 59.07M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $77.795M ▲ $41.245M ▲ $2.169M ▲ 2.788% ▲ $0.037 ▲ $8.995M ▲
Q2-2025 $64.831M ▼ $35.048M ▼ $199K ▲ 0.307% ▲ $0.003 ▲ $8.89M ▲
Q1-2025 $66.379M ▲ $36.151M ▼ $-533K ▼ -0.803% ▼ $-0.009 ▼ $7.956M ▲
Q4-2024 $65.68M ▼ $37.633M ▲ $2.916M ▼ 4.44% ▲ $0.049 ▼ $4.33M ▼
Q3-2024 $68.652M $34.984M $3.045M 4.435% $0.05 $10.484M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $132.022M ▲ $415.513M ▲ $164.144M ▲ $251.448M ▲
Q2-2025 $116.712M ▲ $404.385M ▲ $154.975M ▲ $249.488M ▲
Q1-2025 $104.18M ▲ $390.454M ▼ $141.751M ▼ $248.787M ▲
Q4-2024 $102.304M ▼ $396.336M ▲ $147.844M ▲ $248.578M ▲
Q3-2024 $116.163M $394.658M $147.669M $247.061M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $1.847M ▲ $10.359M ▲ $-5.252M ▼ $9.882M ▼ $14.988M ▲ $5.071M ▲
Q2-2025 $198K ▲ $-27K ▼ $-1.931M ▼ $15.508M ▲ $12.884M ▲ $-4.756M ▼
Q1-2025 $-535K ▼ $9.713M ▲ $-1.757M ▲ $-5.832M ▲ $1.876M ▲ $7.881M ▲
Q4-2024 $2.906M ▼ $6.217M ▼ $-7.533M ▲ $-12.567M ▼ $-13.859M ▼ $-1.543M ▼
Q3-2024 $3.039M $6.869M $-9.951M $-6.088M $-9.329M $-459K

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing steadily over the last five years, with gross profit moving up in parallel, which suggests the core business is gradually scaling. Profitability, however, remains relatively thin. Operating profit and net income are positive but modest, with some bumpiness from year to year and only a small cushion above break-even. Overall, this looks like a company that is past its early-stage losses and is now consistently profitable, but not yet generating strong margins, so it remains sensitive to any slowdown in growth or cost overruns.

Balance Sheet

Balance Sheet The balance sheet appears cautious and generally healthy. Total assets have been stable to slightly higher, while debt has been gradually reduced, leaving the company with more cash than debt and a relatively low financial risk profile. Shareholders’ equity has grown over time, reflecting accumulated earnings and a stronger capital base. In plain terms, the company looks conservatively financed, with room to absorb shocks and continue investing without leaning heavily on borrowing.

Cash Flow

Cash Flow Cash flow from day-to-day operations has been consistently positive, which is a good sign that reported profits are backed by real cash generation. Free cash flow has also been positive in most years, even after funding ongoing investments in equipment and development. Capital spending does move around from year to year, but not to an extreme degree. Overall, the business seems capable of funding its own growth and innovation efforts without constant new financing, though it is not yet a heavy cash generator.

Competitive Edge

Competitive Edge Materialise occupies a specialized position in 3D printing, centered more on software and medical applications than on selling hardware. Its Magics and Mimics platforms are well-regarded, and its long track record and regulatory approvals in healthcare create real hurdles for new entrants. The combination of proprietary software, medical know-how, and integrated printing services gives it a defensible, if not unassailable, niche. Competition from larger 3D printing and software players remains a structural risk, but Materialise’s open, hardware-agnostic ecosystem and medical focus help differentiate it in a crowded field.

Innovation and R&D

Innovation and R&D Innovation is clearly a core part of the strategy. The company is pushing hard into cloud-based platforms (CO-AM), automation tools, and subscription software, aiming to embed itself deeper into customers’ manufacturing workflows. In healthcare, it continues to extend its capabilities in patient-specific implants, surgical guides, and anatomical modeling, all of which lean on heavy R&D and regulatory work. Partnerships with other advanced manufacturing and design firms further amplify this. The flip side is that this level of innovation requires sustained spending and strong execution to turn technical advantages into durable, profitable growth.

Summary

Materialise shows a picture of steady revenue growth, consistent but thin profitability, and a conservative balance sheet with low leverage and positive, recurring cash generation. It has carved out a distinctive position in 3D printing software and personalized medical solutions, supported by deep expertise and regulatory barriers. The company is in the midst of a strategic shift toward cloud platforms and subscription models, which could strengthen recurring revenue but also increases execution risk. Overall, it looks like an innovation-driven, financially prudent business with a focused niche, meaningful upside from successful platform adoption, and ongoing exposure to competitive and margin pressures typical of a still-maturing industry.

NEWS

November 20, 2025 · 2:30 AM UTC

Materialise Successfully Launched on Euronext Brussels – Information on the Total Number of Voting Rights and Shares

Read more

October 30, 2025 · 8:11 AM UTC

Materialise to Hold Extraordinary Shareholders' Meeting on November 14, 2025

Read more

October 30, 2025 · 8:00 AM UTC

Materialise to Pursue Additional Listing on Euronext Brussels and Potential ADS Buyback Program

Read more

October 28, 2025 · 6:30 AM UTC

Materialise Reports Third Quarter 2025 Results

Read more

October 15, 2025 · 4:05 PM UTC

Materialise NV to Report Third Quarter 2025 Earnings on Tuesday, October 28, 2025

Read more